EGFR and non-small cell lung carcinoma: Importantly, actionable KRAS and EGFR alterations make up a significant portion of overall actionable alterations in advanced NSCLC (adenocarcinoma), together accounting for 44% in Western populations and up to 60% in Asian populations [49].